Our mission is to assist our clients in the evaluation of drug efficiency, mechanism, identification of biomarkers in Multiple Myeloma, a cancer that allows introduction of new types of therapeutic molecules for treatment of cancers (proteasome inhibitors, immunomodulators)

Produits et services

Myelomax founders have developed and characterized a large collection of Human Multiple Myeloma Cell Lines covering Multiple Myeloma diversity making the collection a unique tool to study Multiple Myeloma


  • Adresse : IRT 1 8, quai Moncousu 44007 NANTES CEDEX 01
  • Dirigeant : Emmanuelle, MENORET


  • Forme juridique : SAS
  • Capital : 50000
  • NAF : 7219Z
  • Creation date : 03/01/2010
  • Effectif : 2
  • Couverture géographique : oncology
Retour à l'annuaire